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The application of combined chemotherapy and cancer cell permeabilising electric pulses
(electrochemotherapy) has been demonstrated here to be clinically effective in the treat-
ment and control of extensive breast cancer. In this case study the application has proven
to be successful in the palliative treatment of a patient with recurrent breast wall cancer
nodules, where conventional modes of treatment were ineffective in reducing or eliminat-
ing the cancer. This novel therapy offers a new surgical approach for the treatment and
elimination of previously refractory cancers, improving the survival and quality of life
options available to cancer patients.
 2006 Elsevier Ltd. All rights reserved.1. Introduction
Local recurrences which are recalcitrant to multimodal thera-
pies occur in approximately 6% of patients who are treated for
breast cancer.1 Tumour recurrences are often multiple and
progress rapidly resulting in painful skin ulceration, malodor-
ous discharge and bleeding. Such problems are difficult to
manage clinically. In this context surgical resection and chest
wall reconstruction requires prolonged convalescence, is
prone to the complications of wound failure and to further lo-
cal tumour recurrences and is rarely applicable to large-scale
disease particularly if there are systemic metastases. On the
other hand palliative measures are problematic where exten-
sive painful discharging wounds require frequent applica-
tions of dressings. A major problem is the severe
psychological distress for the patient who is witness to theer Ltd. All rights reserved
r Research Centre, Mercy
3 21 4279896.
livan).disease progression and evident therapeutic failure. We re-
port the significant benefit of electrochemotherapy to the
management of an extensive chest wall recurrence of a breast
cancer, after multimodal therapy, which was rapidly progres-
sive and refractory to conventional therapies.
2. Case history
A 47-year-old lady was referred to our centre with an exten-
sive ulcerating tumour on the anterior chest wall (Fig. 1).
She had presented 3 years previously with an inflammatory
cancer of the left breast and with clinically detectable ade-
nopathy in the left axilla. Clinical and radiological investiga-
tion revealed no evidence of distant metastasis. Four cycles
of neo-adjuvant Adriamycin and Cyclophosphamide had
minimally down staged the tumour and a left mastectomy.
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Fig. 1 – Local chest wall recurrence of inflammatory breast
cancer, unresponsive to systemic chemotherapy.
Fig. 2 – Thirty months following initial presentation: the
ulcer has decreased in size dramatically as a result of large
areas of re-epithelialisation and the patient is symptomat-
ically well. Arrow indicates area of local reactivation of
tumour which is decreasing in response to treatment.
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mour showed a 6 cm high grade papillary adenocarcinoma
with positive nodes in all three levels of the axillary dissection
and significant vascular invasion. The tumour was found to
be ER/PR negative but HER2 positive. Postoperatively the pa-
tient received four cycles of Taxol and local field radiation
therapy.
Four months later some inflammatory changes were noted
at the lateral end of the scar. Biopsy confirmed tumour recur-
rence for which Navelbine, Taxotere and Herceptin were com-
menced. The tumour progressed, requiring daily dressings,
and a course of 6 cycles of Gemcitabine was initiated. Spread-
ing inflammatory changes in the right breast were treated
with external beam radiotherapy. A computerised tomogra-
phy (CT) scan at this time revealed pulmonary metastases
but no other systemic disease. The tumour on the left chest
wall was by now a 4.5 · 5 cm, ulcerating lesion and clearly
refractory to conventional therapy (Fig. 1) which was with-
drawn and the patient referred to our service for treatment
with electrochemotherapy.
Under intra-venous sedation the patient received 20,000IU
of bleomycin intravenously and 5000IU intra-tumourally.
Eight minutes after the intra-venous bolus, a consecutive ser-
ies of electric pulses (1400 V/cm intensity, 100 ls duration)
were delivered to the tumour across intra-tumourally placed
linear array needle electrodes. The electrodes were reposi-
tioned until the entire tumour was treated. The patient re-
ceived three such treatments over a 7-month period all of
which were administered in an out-patient setting. The first
two resulted in minimal reduction in tumour volume, with
subsequent progression. However, following the third treat-
ment, a dramatic reduction in the tumour mass was accom-
panied by relief of the pain and bleeding, culminating in a
complete elimination of tumour on the chest wall. Due to this
response systemic chemotherapy was recommenced with 10
cycles of CMF. The remaining ulcer was seen to contract over
time with re-epithelialisation at the periphery (Fig. 2). CT
scanning demonstrated quiescence of the pulmonary lesionsand the chest wall remained tumour-free for ten months.
A subsequent small local recurrence 30 months later has
responded well to further electrochemotherapy and the pa-
tient remains symptomatically well and has declined consid-
eration for skin graft of the residual ulcer.
3. Discussion
This report demonstrates that multiple applications of electr-
ochemotherapy can induce a remission in a locally destruc-
tive breast cancer recurrence, which was refractory to
multimodal therapy. Moreover, electrochemotherapy is
advantageous to patient care as hitherto conventional treat-
ments including surgical intervention and less invasive
oncology choices are limited in their ability to effectively
localise treatment to cancerous tissues without causing dis-
ruption to non-target physiological tissues, functions and or-
gans.2 Because of its therapeutic efficacy and minimal side
effects electrochemotherapy could with benefit be applied
earlier in the clinical course of locally recurrent cancers and
would be tolerated when used in combination with standard
systemic agents. It is noteworthy that tumours respond to
electrochemotherapy even when resistant to conven-
tional regimens and when recurrent after previous
electrochemotherapy.
Extensive chestwall recurrences are rarely suitable for exci-
sion and chest wall reconstruction. Colonisation of the ulcers
by bacteria and radiation injury to the surrounding tissues pre-
dispose the patient to wound infection and failure after sur-
gery. While some of these problems can be overcome by
reconstructing with free transfer grafts because of the scale
of the surgery and the protracted duration of convalescence
the cancer has often recurred prior to rehabilitation of the pa-
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prone to recur at variable periods after excision so multiple
interval therapies are warranted and extensive excision is
rarely curative. Electrochemotherapy has been established as
an effectivemeansof treating tumours that present as primary
and secondary cutaneous, sub-cutaneous and local recur-
renceswhich prove to be refractory to conventional treatment.
Diverse tumour types which are responsive to electrochemo-
therapy include metastatic malignant melanoma, squamous
cell carcinoma, basal cell carcinoma and recurrent breast ade-
nocarcinoma.3–5 Electrochemotherapy is ideally suited tomul-
tiple applications and the cumulative dose of bleomycinwould
rarely approach levels associated with side effects or toxicity.
Our experience with this patient was very gratifying where
multiple applications of electrochemotherapy, applied during
out-patient visits, resulted in tumour regression and an imme-
diate improvement in quality of life.
Current limitations of this treatment include its restricted
suitability for cutaneous and subcutaneous tumours, how-
ever, a myriad of unresectable symptomatic cancers could
benefit from the development of new electrodes and operat-
ing procedures. The development of such technology capable
of delivering permeabilising electric pulses to intraluminal
gastrointestinal or urinary tract tumours endoscopically, or
to intra-abdominal tumours via the laparoscopic approach
may ensure that a great many tumours which are now
deemed inoperable or are unresponsive to conventional ther-
apy would then be accessible to electrochemotherapy. Tu-
mour burden reduction or tumour regression would be a
feasible aim, facilitating the achievement of palliation of
symptoms, improvement of quality of life, prolongation of
survival and perhaps cure.6 Moreover, the role, this technol-
ogy may play in the delivery of immunologically active imper-
meant molecules or cytokines to tumours is an exciting area
of current research. The manifold benefits possible from the
introduction of such therapies may allow for the development
of innate immunological protection against the development
of metastatic disease and as such would represent a thera-
peutic advance.74. Conclusion
Electrochemotherapy induced a clinically significant remis-
sion of a progressive and destructive chest wall recurrence
of a breast cancer which was refractory to multimodal thera-
pies. A delayed tumour recurrence at 30 months was again
responsive to the electrochemotherapy. Tumour regression
was accompanied by a dramatic improvement in quality of
life. This experience in aggressive refractory cancer suggests
that electrochemotherapy techniques should be developed
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